Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential BCG and EMDA-mitomycin C vs BCG alone in high-risk non-muscle-invasive bladder cancer
2018-000150-22Phase 3Active
- Sponsor
- Turku University Hospital
- Start
- May 2018
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bcg vaccine and mitomycin c in bladder cancer (2 arms), sponsored by Turku University Hospital. Primary endpoint: Recurrence. Started May 2018; status: active.
02
Drugs
bcg vaccinemitomycin c
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2018-000150-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000150-22.